The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Structure-Based Search for New Inhibitors of Cholinesterases
Open accessAbstract
Cholinesterases are important biological targets responsible for regulation of cholinergic transmission, and their inhibitors are used for the treatment of Alzheimer’s disease. To design new cholinesterase inhibitors, of different structure-based design strategies was followed, including the modification of compounds from a previously developed library and a fragment-based design approach. This led to the selection of heterodimeric structures as potential inhibitors. Synthesis and biological evaluation of selected candidates confirmed that the designed compounds were acetylcholinesterase inhibitors with IC50 values in the mid-nanomolar to low micromolar range, and some of them were also butyrylcholinesterase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126
Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., & Silman, I. (1991) · Science · doi:10.1126/science.1678899 · Cited by 2,707
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 1×
“Since the cholinergic hypothesis was approved, cholinesterases have become important therapeutic targets in Alzheimer’s disease (AD) treatment [1].”
BackgroundOllis, D. L., Cheah, E., Cygler, M., Dijkstra, B., Frolow, F., Franken, S. M., Harel, M., Remington, S. J., Silman, I., Schrag, J., et al. (1992) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/5.3.197 · Cited by 2,120
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.
Harel, M., Schalk, I., Ehret-Sabatier, L., Bouet, F., Goeldner, M., Hirth, C., Axelsen, P. H., Silman, I., & Sussman, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.9031 · Cited by 899
Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products
Nicolet, Y., Lockridge, O., Masson, P., Fontecilla-Camps, J. C., & Nachon, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210241200 · Cited by 840
Kryger, G., Silman, I., & Sussman, J. L. (1999) · Structure · doi:10.1016/s0969-2126(99)80040-9 · Cited by 757
Abola, E. E., Bernstein, F. C., & Koetzle, T. F. (1984) · Neutrons in Biology · doi:10.1007/978-1-4899-0375-4_26 · Cited by 735
Cygler, M., Schrag, J. D., Sussman, J. L., Harel, M., Silman, I., Gentry, M. K., & Doctor, B. P. (1993) · Protein Science · doi:10.1002/pro.5560020309 · Cited by 565
Cholinesterase inhibitors: new roles and therapeutic alternatives
GIACOBINI, E. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.11.017 · Cited by 555
Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacology
Silman, I., & Sussman, J. L. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.01.014 · Cited by 524
Johnson, G., & Moore, S. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775193127 · Cited by 321
Alvarez, A., Alarcón, R., Opazo, C., Campos, E. O., Muñoz, F. J., Calderón, F. H., Dajas, F., Gentry, M. K., Doctor, B. P., De Mello, F. G., et al. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03213.1998 · Cited by 317
Tacrine Derivatives and Alzheimers Disease
Tumiatti, V., Minarini, A., Bolognesi, M. L., Milelli, A., Rosini, M., & Melchiorre, C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791111206 · Cited by 225 · cited 1×
“huperzine [6,24].”
Therapies for Alzheimer's disease
Melnikova, I. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2314 · Cited by 219
Targeting acetylcholinesterase to treat neurodegeneration
Holzgrabe, U., Kapková, P., Alptüzün, V., Scheiber, J., & Kugelmann, E. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.161 · Cited by 217
Recent Developments in Cholinesterases Inhibitors for Alzheimers Disease Treatment
Musial, A., Bajda, M., & Malawska, B. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707782023217 · Cited by 195
Self-citationRountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181
Darvesh, S., Cash, M. K., Reid, G. A., Martin, E. V., Mitnitski, A., & Geula, C. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31823cc7a6 · Cited by 159
Koellner, G., Kryger, G., Millard, C. B., Silman, I., Sussman, J. L., & Steiner, T. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3468 · Cited by 146
Masson, P., Legrand, P., Bartels, C. F., Froment, M.-T., Schopfer, L. M., & Lockridge, O. (1997) · Biochemistry · doi:10.1021/bi962484a · Cited by 138
Xu, Y., Colletier, J., Weik, M. H., et al. (2008) · Biophysical Journal · doi:10.1529/biophysj.108.129601 · Cited by 129
Camps, P., Formosa, X., Galdeano, C., Gómez, T., Muñoz‐Torrero, D., Ramírez, L., Viayna, E., Gómez, E., Isambert, N., Lavilla, R., et al. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.02.013 · Cited by 87
Molecular Design. Concepts and Applications
Fraga, C. A. M. (2009) · Americanae (AECID Library) · doi:10.3395/reciis.v3i2.805 · Cited by 81
Luo, W., Li, Y., He, Y., Huang, S., Tan, J., Ou, T., Li, D., Gu, L., & Huang, Z. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.022 · Cited by 81
Du, D., & Carlier, P. R. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383412 · Cited by 71
Nachon, F., Ehret‐Sabatier, L., Loew, D., Colas, C., DORSSELAER, A. V., & Goeldner, M. P. (1998) · Biochemistry · doi:10.1021/bi980536l · Cited by 58
Ignasik, M., Bajda, M., Szałaj, N., Prinz, M., Holzgrabe, U., & Malawska, B. (2012) · Archiv der Pharmazie · doi:10.1002/ardp.201100423 · Cited by 56
Self-citationChen, X., Tikhonova, I. G., & Decker, M. W. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.034 · Cited by 53
Yan, J., Li, Y., Ye, W.-J., Chen, S.-B., Hou, J., Tan, J., Ou, T., Li, D., Gu, L., & Huang, Z. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.02.061 · Cited by 52
Progress in the history of Alzheimer's disease: The importance of context
Ballenger, J. F. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s302 · Cited by 42
Więckowska, A., Bajda, M., Szałaj, N., & Malawska, B. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.09.010 · Cited by 24
Self-citationTHE DESIGN AND SYNTHESIS OF PURINE INHIBITORS OF CDK2. III
Shum, P. W., Peet, N. P., Weintraub, P. M., Le, T. B., Zhao, Z., Barbone, F. P., Cashman, B., Tsay, J. T., Dwyer, S. D., Loos, P., et al. (2001) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1081/ncn-100002493 · Cited by 17
Quici, S., Manfredi, A., Pozzi, G., Cavazzini, M., & Rozzoni, A. (1999) · Tetrahedron · doi:10.1016/s0040-4020(99)00573-6 · Cited by 13
Cited by
Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323
“Dual-acting compounds with cholinesterase and A aggregation inhibitory activities were identified in a series of 2(aminoalkyl)-isoindoline-1,3-dione derivatives [87, 88].”
BackgroundSelf-citationWięckowska, A., Kołaczkowski, M., Bucki, A., Godyń, J., Marcinkowska, M., Więckowski, K., Zaręba, P., Siwek, A., Kazek, G., Głuch-Lutwin, M., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.016 · Cited by 91
Self-citationAnti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
Amat-ur-Rasool, H., Ahmed, M., Hasnain, S., & Carter, W. G. (2021) · Brain Sciences · doi:10.3390/brainsci11020184 · Cited by 43
“The catalytic region of AChE (the esteratic site) is located at the bottom of a narrow gorge and contains three essential amino acids that provide the catalytic triad [24,40].”
BackgroundMetformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity
Markowicz-Piasecka, M., Sikora, J., Mateusiak, Ł., Mikiciuk-Olasik, E., & Huttunen, K. M. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/7303096 · Cited by 32
Metadata
- Authors
- Bajda, M., Więckowska, A., Hebda, M., Guzior, N., Sotriffer, C., & Malawska, B.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2013-03-11
- Volume
- 14
- Issue
- 3
- Pages
- 5608-5632
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2067171548
- Cited by
- 274
- References
- 35
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.